ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease

12-Feb-2010 - France

ExonHit Therapeutics S.A. announced that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog). PharmaCog focuses on translational science and harmonization of research tools. Ultimately PharmaCog should provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines.

PharmaCog stands for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a cross party project, cocoordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, Marseille, France. It brings together top scientists from 5 small and medium size enterprises, 11 global pharmaceutical companies, 12 academic institutions; in addition, 1 patient group representing 9 countries across Europe will ensure the dissemination of PharmaCog results. The European Medicines Agency (EMA), an associated partner of the project, will share project progress and discuss the implications for drug development in Europe.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...